Drugmakers are playing omicron whack-a-mole when the focus should be on a new generation of pan-coronavirus shots.
By Lisa Jarvis | Bloomberg, Washington Post: Business
Fri, 01/21/2022 - 10:07am
Drugmakers are playing omicron whack-a-mole when the focus should be on a new generation of pan-coronavirus shots.